We demonstrated that the systemic application of expanded CD133+ cells or expanded CD133+ cell-derived EVs, in fact, was not an appropriate route for the treatment of ischemic cardiomyopathy. This evidence concerns the gene PROM1 and ischemic cardiomyopathy.